Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Cross-Talk between Inducible Nitric Oxide Synthase and Cyclooxygenase in Helicobacter-pylori-Induced Gastritis

Franco L.a · Talamini G.b

Author affiliations

aSection of Pharmacology, Department of Medicine and Public Health, and bDepartment of Surgical and Gastroenterological Sciences, University of Verona, Verona, Italy

Corresponding Author

Dr. Luigina Franco

Department of Medicine and Public Health, Section of Pharmacology

University of Verona, Policlinico G. Rossi, P.le L.A. Scuro 10

IT–37134 Verona (Italy)

Tel. +39 045 802 7604, Fax +39 045 802 7452, E-Mail Luigina.Franco@univr.it

Related Articles for ""

Med Princ Pract 2009;18:477–481

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Objectives: The present study examined the cross-talk between prostanoids and nitric oxide (NO) in human gastric biopsies during Helicobacter pylori infection. Subjects and Methods: A pool of 1 or 2 biopsies per patient (11 H. pylori positive and 9 H. pylori negative) were incubated in the medium with/without drugs, 1400W and NS-398, inhibitors of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2), respectively. Levels of NO and prostaglandin E2 (PGE2), predominant products of activity of NOS and COX enzymes, were measured in the medium whereas the expressions of iNOS and COX protein, examined by Western blotting, were measured in the biopsies. Results: The 11 patients with H. pylori infection showed a marked expression of COX-2 and iNOS proteins and high levels of PGE2 and NO, as a consequence of iNOS and COX-2 activation, while proteins were absent and the level of nitrite and PGE2 was low in the 9 noninfected patients. The COX-2 inhibitor decreased both NO and PGE2. The iNOS-specific inhibitor decreased NO but did not have any effect on the increase in gastric mucosal PGE2. Both inhibitors had no effect on the protein level of these two enzymes. Conclusions: The data showed that COX-2 inhibitor might modulate the iNOS pathway, suggesting that COX-2 activity and/or its products may be related to the functional activation of iNOS but not to the expression of iNOS protein.

© 2009 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: July 16, 2008
Accepted: January 27, 2009
Published online: September 30, 2009
Issue release date: October 2009

Number of Print Pages: 5
Number of Figures: 2
Number of Tables: 1

ISSN: 1011-7571 (Print)
eISSN: 1423-0151 (Online)

For additional information: http://www.karger.com/MPP


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.